Vivos Inc

Vivos Inc. on the OTC Bulletin Board: market cap, price swings, and a negative P/E hint at future growth potential amid volatility.

Vivos Inc. accelerates its yttrium‑90 precision oncology platform, boosting IsoPet® in veterinary oncology and advancing RadioGel® toward FDA approval—while expanding IP, manufacturing, and global reach to sustain growth in the competitive cancer‑tr…

Vivos Inc. shares on the OTC Bulletin Board hit $0.09 in 2026, amid a 52‑week high of $0.1657 and a market cap of $42M, but a negative P/E signals investor challenges.

Vivos Inc. unveils a bold expansion plan to boost global manufacturing and diversify growth, despite current financial challenges and volatile share prices.

Vivos Inc. expands manufacturing globally to boost growth, despite volatile stock and negative earnings; investors watch as expansion could reverse its financial trajectory.

Vivos Inc. faces sharp volatility and negative P/E/B ratios, leaving investors wary despite therapeutic progress—understand the risks before buying.

Vivos Inc.

Vivos Inc’s animal therapy progress faces a harsh backdrop: negative P/E and P/B ratios, low stock price, and investor skepticism. Is innovation enough to lift its health‑care valuation?

Vivos Inc. (OTC) faces volatility and a negative P/E, but seeks strategic growth and operational efficiency to boost its market position.

Vivos Inc. on the OTC Bulletin Board: volatile stock, a $35M market cap, negative P/E, and the strategic path to profitability and investor trust.